Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Denmark
/
Pharmaceuticals & Biotech
Create a narrative
ALK-Abelló Community
CPSE:ALK B Community
1
Narratives
written by author
0
Comments
on narratives written by author
23
Fair Values set
on narratives written by author
Create a narrative
ALK-Abelló
Popular
Undervalued
Overvalued
Community Investing Ideas
ALK-Abelló
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
Allergy+ Strategy Will Reach Millions With New Therapies
Key Takeaways Expanding into new patient groups and segments will drive long-term revenue growth in respiratory allergies and broader allergy space. Focus on optimizing operations and increasing production capacity can enhance margins and earnings, supported by strategic initiatives in key markets.
View narrative
DKK 180.75
FV
1.6% undervalued
intrinsic discount
12.40%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
15
users have followed this narrative
about 5 hours ago
author updated this narrative
Your Valuation for
ALK B
ALK B
ALK-Abelló
Your Fair Value
DKK
Current Price
DKK 177.90
27.1% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-149m
10b
2015
2018
2021
2024
2025
2027
2030
Revenue DKK 10.0b
Earnings DKK 1.6b
Advanced
Set Fair Value